Keyphrases
Hedgehog
100%
Phase 1 Trial
100%
Resectable Pancreatic Cancer
100%
Sirolimus
100%
MTOR Pathway
100%
Vismodegib
100%
Mammalian Target of Rapamycin (mTOR)
40%
Maximum Tolerated Dose
40%
Dose-limiting Toxicity
40%
Antitumor Efficacy
40%
Thrombocytopenia
40%
Stable Disease
40%
Preclinical Data
20%
Clinical Benefit
20%
Molecular Interactions
20%
Gli1
20%
Functional Interaction
20%
Downstream Targets
20%
Pancreatic Ductal Adenocarcinoma
20%
Dehydration
20%
PI3K-AKT-mTOR Pathway
20%
Phase I Study
20%
Dose Level
20%
Orally Administered
20%
Clinical Model
20%
Complete Response
20%
Partial Response
20%
GLI Signaling
20%
First Cycle
20%
Advanced Solid Tumors
20%
One Dose
20%
Metastatic Pancreatic Ductal Adenocarcinoma
20%
2-cycles
20%
Mucositis
20%
Tumor Patients
20%
3 + 3 Design
20%
Paired Biopsies
20%
Targeting Efficacy
20%
Target Assessment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Hedgehog
100%
Pancreas Cancer
100%
Rapamycin
100%
Vismodegib
100%
Disease
40%
Neoplasm
40%
Maximum Tolerated Dose
40%
Pancreas Adenocarcinoma
40%
Thrombocytopenia
40%
Infection
20%
Solid Malignant Neoplasm
20%
Mucosa Inflammation
20%
Immunology and Microbiology
Sirolimus
100%
Hedgehog
100%
Maximum Tolerated Dose
40%
Molecular Interaction
20%
mTOR Signaling
20%